Serrated polyposis (SP) is a clinically defined syndrome characterized by the occurrence of multiple serrated polyps in the large intestine. Individuals with SP and their relatives are at increased risk of colorectal carcinoma (CRC). We aimed to determine the pathologic and molecular profiles of CRCs in individuals fulfilling World Health Organization criteria for SP. A total of 45 CRCs were obtained from 38 individuals with SP (27 female and 11 male patients; median age at CRC diagnosis, 58.5 y) attending genetics clinics. Tumor samples were pathologically reviewed, screened for somatic BRAF and KRAS mutations, and analyzed immunohistochemically for mismatch repair protein (MMR) expression. Tumors were spread throughout the large intestine, with 64% located in the proximal colon. Mutations in BRAF and KRAS and immunohistochemical evidence of MMR deficiency were found in 46%, 5%, and 38%, respectively. Nearly half of CRCs were BRAF/KRAS wild type, and these were associated with distal location (63%) and MMR proficiency (84%). Overexpression of p53 and/or evidence of b-catenin activation were identified in 13 CRCs. Ten patients (26%) had synchronous or metachronous CRCs. In conclusion, the majority of CRCs arising in individuals with SP do not harbor molecular hallmarks of serrated pathway CRCs but show a diverse range of molecular profiles. The high proportion of multiple CRCs suggests that individuals with SP would benefit from frequent colonoscopic surveillance and from a consideration of a more extensive colectomy at the time of CRC diagnosis.
PTEN, or GREM1. 5, 6 The remaining unexplained CRCs with a familial component may be the result of a combination of unknown minor genetic defects, mutations in yet to be identified susceptibility genes, and environmental risk factors shared by relatives.
Serrated polyposis (SP) is a CRC predisposition syndrome [7] [8] [9] [10] [11] [12] with an established familial risk for CRC but without a known genetic basis. 7, 13 The hallmark of SP is the presence of multiple serrated polyps (hyperplastic polyps and sessile serrated adenomas/polyps) in the large intestine. It was previously suggested that the polyp burden and the co-occurrence of conventional adenomas increased the risk of CRC in patients with SP. 8, 9, 14 CRCs develop through different molecular pathways that involve sequences of genomic and epigenomic alterations associated with pathologic and clinical features: the serrated neoplasia pathway and the traditional adenoma pathway. Mutation in BRAF, along with CpG island methylator phenotype, is the molecular marker of serrated neoplasia pathway CRC, in which serrated polyps are thought to be the precursor lesions. 15, 16 Alternatively, WNT/CTNNB1 alterations and KRAS and TP53 mutations are common genetic events in traditional adenoma pathway CRC. Another major molecular classifier of CRC is microsatellite instability, present in most but not all serrated neoplasia pathway CRCs and, less frequently, in Lynch syndrome-associated CRC. Similar to FAP representing a model of CRC evolving through the traditional adenoma pathway, SP may represent a model of CRC evolving through the serrated neoplasia pathway. However, despite the presence of multiple serrated polyps, small numbers of conventional adenomas are often also documented in SP individuals. Although they are not the predominant polyp type, the presence of conventional adenomas in SP is associated with an increased risk of CRC in these individuals. 9, 14 Hence, in contrast to FAP, SP may not be a model for CRC evolving purely through the serrated neoplasia pathway. In this study, we sought to characterize the pathologic and molecular features of CRC in a large cohort of welldocumented individuals with SP in order to identify their lesion of origin for CRC in SP, to improve our understanding of the disorder, and to facilitate the development of prevention and surveillance strategies.
MATERIALS AND METHODS

Patient Selection
A cohort of individuals with at least 5 serrated polyps proximal to the rectosigmoid region was selected from patients recruited to a registry between 2000 and 2011 in Australia, New Zealand, Canada, and the United States. These individuals with a suspected polyposis syndrome and/or family history of CRC were referred by gastroenterologists to tertiary center genetics clinics. Written informed consent for participation in the research was obtained from all individuals, and the study was approved by the Human Research Ethics Committee of Queensland Institute of Medical Research under the Genetics of Serrated Neoplasia Project (QIMR HREC P912). From this registry, we sought all CRC cases. Clinical data were collected from medical charts, colonoscopy reports, and pathology reports. Standard whitelight colonoscopy was used in all patients. The cumulative number and distribution of polyps were recorded from colonoscopy and pathology reports on polyp biopsies and surgical resection specimens. To be selected for the study, patients had to meet either criterion (1) or (3) of the 2010 World Health Organization (WHO) criteria for SP 17 : (1) at least 5 serrated polyps proximal to the sigmoid colon with 2 or more of these being >10 mm; or (3) >20 serrated polyps of any size but distributed throughout the colon. No patient was selected purely on the basis of criterion (2) (any number of serrated polyps proximal to the sigmoid colon in an individual who had a first-degree relative with SP). Only CRC cases with available tissue for pathologic review were included in the series. For statistical analysis, location in the colon was designated as proximal for tumors located in the cecum, ascending colon, and transverse colon and as distal in the descending colon, sigmoid colon, and rectum.
Tissue Specimens
Formalin-fixed paraffin-embedded tissue blocks were retrieved for all selected CRC specimens. A pathologic review from hematoxylin and eosin-stained tissue sections was performed by 3 specialist gastrointestinal pathologists (Jeremy Jass, N.I.W., and C.R.). The CRCs were assessed histologically for the following features: histologic type (including serrated adenocarcinoma subtype), tumor grade, presence of tumor-infiltrating lymphocytes, and residual polyp adjacent to the carcinoma. Pathologic staging was performed according the American Join Committee on Cancer (AJCC) system, seventh edition, 2010. Polyps were classified into conventional adenomas or different categories of serrated polyps according to the WHO criteria. 17 
Molecular Analysis
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue using QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. V600E BRAF mutation analysis was performed by a fluorescent allele-specific polymerase chain reaction assay to detect the somatic T > A mutation at nucleotide 1799 in exon 15, as previously described. 9 Somatic mutations in codons 12 and 13 of KRAS were screened using real-time polymerase chain reaction with high resolution melting analysis in the presence of the SYTO9 fluorescent intercalating dye, followed by direct Sanger sequencing in cases with differential melting profiles, as previously described. 14 of MSH2 and/or MSH6 or MLH1/PMS2 with wild-type BRAF underwent germline mutation testing (Sanger sequencing and MLPA) of the MMR gene indicated by the pattern of loss from IHC. 19 When available, additional tissue sections were used to assess for IHC expression of p53 (clone DO7; Cell Marque, Rocklin, CA; dilution 1:100) and b-catenin (clone 14; Cell Marque; dilution 1:600). Heat-induced epitope retrieval was performed for both immunostains using Reveal Decloaker RTU solution (Biocare Medical, Concord, CA). The Dako autostainer was used for all immunostains. Expression of p53 proteins in tumor cells was semiquantitatively scored as 0 for no expression; 1 for <10%, 2 for 11% to 25%; 3 for 26% to 50%; 4 for 51% to 75%; and 5 for >75% expression. Only tumors scoring 3 or more were considered positive for p53 overexpression. Assessment of b-catenin expression was undertaken as follows: lateral membrane expression (score 0 if present and 1 if absent), cytoplasmic staining (score 0, 1, or 2 for none, weak, and strong expression, respectively), and nuclear expression (score 0, 1, or 2 for none, weak, and strong expression, respectively). Tumors showing a combined score of 4 or 5 were classified as positive altered expression of b-catenin.
Statistical Analysis
We used the Pearson w 2 test or the Fisher exact test as appropriate to compare categorical variables. The Student t test was used for continuous variables. A 2tailed P value was used for all analyses, and a P value of <0.05 was used to determine statistical significance. All statistical analyses were performed using SPSS statistics software version 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of SP Patients With CRC
Forty-six cases of CRC were identified from 39 patients fulfilling at least WHO criterion 1 or 3 for SP. One male patient, 19 years old at the time of CRC diagnosis, was found to be an MSH2 mutation carrier after IHC analysis demonstrated loss of MSH2/MSH6 expression in tumor cells. This patient also had 28 histologically documented serrated polyps in the large intestine (WHO criterion 3 for SP) and was excluded from the study. No other patient was found to carry a germline mutation in an MMR gene. The final patient cohort comprised 45 CRCs from 38 patients. Twenty-two of these patients overlapped with our previous study, which focused on describing the histologic and molecular characteristics of polyps associated with SP individuals. 14 The additional 16 patients included in this cohort were newly enrolled individuals or individuals not initially selected because of lack of sufficient information at the time of the previous study. There were 9 patients meeting criterion 1 only, with serrated polyp counts ranging from 6 to 20 ( Table 1 ). The remaining patients had a serrated polyp count between 21 and 109, fulfilling criterion 3. A family history of CRC in first-degree or second-degree relatives was reported in 16 of 27 patients (59.3%) for whom this information was available. At least 1 conventional adenoma was present in 40 patients (88.9%). The mean number of conventional adenomas per patient was 4.7 (SD 3.1). None of the patients was diagnosed with a colonic hamartomatous polyp, making hereditary mixed polyposis syndrome an unlikely diagnosis. The median age of SP patients at diagnosis of first CRC was 58.5 years, ranging from 18 to 76 years. The female to male sex ratio was 2.4:1.
Synchronous CRCs occurred in 4 patients, and 3 patients had metachronous CRC with an interval of 10, 11, and 16 years, respectively, between both malignancies. Multiple CRCs were reported in 3 additional patients: 1 patient had a total of 4 carcinomas with a surgical resection for a CRC, followed by 2 synchronous CRCs and then the carcinoma 7 years later that was reviewed and analyzed; 1 patient had 2 CRCs 13 and 19 years before the CRC that was reviewed; and 1 patient had a synchronous, stage pT1, CRC arising from a sessile serrated adenoma with cytologic dysplasia described in the pathology report, for which no tissue was available. Altogether, 10 of 38 patients (26.3%) in this series, comprising 6 female and 4 male patients, had synchronous or metachronous CRCs. The median interval between metachronous CRC was 10.5 years, ranging from 6 to 13 years. Synchronous CRCs among the 6 patients with a total of 15 tumors were confined to the proximal colon for 11 (73%) and the distal colon for 4 (27%) tumors. This distribution was not statistically different from the distribution of nonsynchronous CRCs (P = 0.52). There was no association between the presence of family history and the occurrence of multiple CRCs.
Pathologic Characteristics of CRC
All 38 patients with CRCs underwent partial or total colectomy. The distribution of the 45 CRCs is represented in Figure 1 and Table 2 . There were 29 CRCs (64%) located in the proximal colon and 16 CRCs in the distal colorectum. As displayed in Table 2 , the main histologic subtype was adenocarcinoma of no specific type (71.1%), followed by mucinous adenocarcinoma (22.2%) and serrated adenocarcinoma (6.7%). A minor mucinous component (< 50% of tumor analyzed) was 
Molecular Phenotype of CRC
To classify CRC molecularly, we performed screening for BRAF and KRAS somatic mutations and IHC analysis for expression of MMR proteins MLH1, PMS2, MSH2, and MSH6. In a subset of tumors (n = 25), additional unstained paraffin sections were available to stain for p53 and/or b-catenin. A V600E mutation in BRAF was identified in 18 of 39 CRCs (46.2%), and a KRAS mutation was found in 2 of 40 tumors (5.0%) with sequence variants of c.34G > C and c.35G > A, respectively. Loss of IHC expression of MLH1 and PMS2 proteins was found in 17 of 45 tumor samples (37.8%). Tumors with the BRAF mutation were more likely to have MMR deficiency compared with BRAF wild-type CRCs (76.5% vs. 14.3%; P < 0.001).
Results were available for BRAF, KRAS, and MMR testing on 38 tumor samples ( Table 3 ). As displayed in Figure 2 , CRCs were classified in 5 categories according to their status for combinations of BRAF mutation, KRAS mutation, and MMR deficiency. The largest group of tumors (40%) had a BRAF and KRAS wild-type/MMR-proficient phenotype, followed by BRAF-mutated/MMR-deficient phenotype (34%).
IHC overexpression of p53 was identified in 8/25 cases (32%), including 2 BRAF-mutated/MMR-deficient CRCs, 4 BRAF and KRAS wild-type/MMR-proficient CRCs, and 2 MMR-proficient CRCs with unknown KRAS or BRAF status. IHC evidence of b-catenin activation was identified in 8/24 CRCs (33.3%). Two cases were BRAF-mutated/MMR-deficient CRCs (1 with p53 overexpression and 1 with normal p53), and the other 6 were BRAF and KRAS wild-type/MMR-proficient CRCs. Combined p53 overexpression and b-catenin activation was present in 1 BRAF-mutated/MMR-deficient CRC and 2 BRAF and KRAS wild-type/MMR-proficient CRCs.
Correlation Between Molecular Findings and Clinicopathologic Characteristics
A positive correlation was found between BRAFmutated CRC and female sex (P = 0.05), proximal tumor location (P < 0.001), mucinous or serrated adenocarcinoma histologic type (P < 0.001), and the presence of tumorinfiltrating lymphocytes (P = 0.04) (Table 4) . Similarly, MMR-deficient CRC correlated positively with proximal tumor location (P = 0.001), mucinous or serrated adenocarcinoma histologic type (P = 0.001), the presence of tumor-infiltrating lymphocytes (P < 0.001), and lower tumor stage (P = 0.02). The BRAF mutation was present in 5/9 (56%) CRCs with a contiguous serrated polyp and in none of the 4 CRCs with a contiguous conventional adenoma. For 4 patients who developed 2 synchronous CRCs, molecular testing was available for all 8 tumors. In 2 patients, both tumors had a similar molecular profile Table 5 . Although the numbers are small for statistical analysis, CRCs with an adjacent traditional serrated adenoma or a sessile serrated adenoma demonstrated more frequent mucinous differentiation, BRAF mutation, and MMR deficiency.
DISCUSSION
An increased risk of CRC is seen in individuals with SP and has been associated with the presence of conventional adenoma. 7, 8, 13, 14 Therefore, in this study, we sought to understand the developmental sequence of the CRC observed in SP patients. The reported incidence of CRC from published series of SP patients (>20 patients) varies from 14% to 54%. 7, 9, 12, 14, [20] [21] [22] Although this range is wide, even at its lower limit, it represents a significant increase in risk over the general population. The differences between series may be at least partially explained by the type of population studied. The lowest incidence has been reported from unselected population cohorts, whereas the highest incidence has been found from cohorts of patients referred to genetic clinics. The latter may represent a recruitment bias for patients with a strong family history and CRC at time of polyposis diagnosis. However, the actual risk of CRC in SP patients is still uncertain for several reasons. Firstly, the prevalence of SP in the general population is unknown, and likely to be underrecognized, as most patients with uncomplicated colorectal serrated polyps, even if multiple, may remain asymptomatic. In a large populationbased screening trial of asymptomatic patients aged between 55 and 64 years, SP was prospectively identified at a rate of 1 in 3000 individuals. 23 However, most published series of SP patients reported a broad range of age distribution (17 to 85 y) and a mean age at SP diagnosis of between 47.7 and 56 years. [7] [8] [9] 11, 12 Therefore, it is possible that the prevalence of SP in the general asymptomatic population, which includes individuals between 55 and 64 years of age, may be higher than 1 in 3000 cases currently reported. Moreover, it has recently been shown that SP is underdiagnosed because of lack of awareness of the syndrome among gastroenterologists and surgical pathologists. 24, 25 Secondly, a large proportion of SP patients are likely to have a first diagnosis of SP at the time of presentation with CRC, and this will precipitate referral to genetics clinics, thereby inflating the reported rate of CRC from this biased population. Finally, it is difficult to identify patients with SP and conduct prospective studies without a genetic alteration to define this condition. Although the genetic basis for SP has yet to be discovered, a body of evidence suggests an inherited genetic basis: common ethnicity background found in many SP patients with a Northwestern European ancestry, 10, 11, 22 frequent familial clustering of SP individuals, 11, 12, 21, 26 and the recently described increased risk of colorectal and pancreatic cancers in first-degree and second-degree relatives of SP patients. 13 Studying SP patients referred to genetics clinics allows researchers to collect a unique cohort of symptomatic SP patients with CRC. In this study, we aimed to understand the origin of CRC arising in SP patients and selected individuals with SP who likely represented the most severe clinical phenotype. This allowed us to readily obtain a large number of individuals with SP and CRC, which would not be available in a population study. The rate of BRAF mutation in SP CRC (46.2%) was higher than the mutation rate reported in CRC from the general population (10% to 20%). [27] [28] [29] As previously reported for population studies, BRAF-mutated CRCs in SP were associated with female sex, proximal colonic location, mucinous histologic subtype, and presence of tumor-infiltrating lymphocytes. 30, 31 In contrast, the rate of KRAS mutation was considerably lower than that seen in the general population (5% vs. >30%). However, the majority of CRCs in SP patients were wild type for both BRAF and KRAS. Moreover, we found molecular alterations commonly associated with the traditional adenoma carcinoma pathway in 13 CRCs demonstrating IHC overexpression of p53 and/or evidence of b-catenin activation. These results are consistent with those of Boparai et al 32 who reported, in a series of 19 CRCs from SP patients, BRAF mutation in 53%, b-catenin activation in 26%, and p53 overexpression in 42%. Although the expression of b-catenin has been previously reported in serrated polyps, 33 it was always associated with BRAF mutation. In our study, however, activation of b-catenin was found in CRCs with or without BRAF mutation.
These findings demonstrate that a large proportion of CRCs from SP patients do not develop through the canonical serrated neoplasia pathway (driven by BRAF mutation) but show various molecular phenotypes including those more likely to be associated with the common CRC traditional adenoma pathway. Although KRAS mutation was rare in this series, these few may represent fusion pathway CRCs. 30 This poorly recognized subgroup of CRCs is reportedly associated with low levels of CpG island methylator phenotype and microsatellite instability, downregulation of MGMT by methylation, and frequent KRAS mutation. 16, 30 Pai et al 34 described a new polyp entity, the so-called atypical conventional adenoma, found in individuals who also have at least 1 sessile serrated adenoma. These polyps share some morphologic characteristics with serrated polyps and were all BRAF/KRAS wild type. This polyp subtype may possibly be the precursor lesion of the vast majority of CRCs in SP 35 and are likely to be the precursor lesion of most CRCs evolving through the serrated neoplasia pathway. In our series, 5 of the 9 CRCs (55.5%) with a residual contiguous serrated polyp harbored the V600E mutation in BRAF. We previously showed that the presence of conventional colorectal adenomas in SP was associated with the occurrence of CRC, suggesting that at least some CRCs may develop from conventional adenomas. 9, 14 In our current series, the majority of patients (88.9%) had at least 1 conventional adenoma identified separate from the CRC. However, only 4 CRCs had a residual contiguous conventional adenoma, a relatively small number, possibly secondary to overgrowth of the precursor polyp by the carcinoma in some cases or because of insufficient tumor sampling. This suggests that CRC in SP patients may develop from nonserrated polyps through either a derivative of the traditional adenoma pathway. SP could therefore, potentially, be considered a disorder associated with a hypermature or inappropriately aged colonic mucosa, possibly secondary to an alteration in DNA methylation, with a resultant propensity to the development of earlyonset multiple serrated polyps and conventional adenomas, as described by Pai et al. 34 The molecular subtype of CRC, which may develop in SP patients, will reflect the histologic type of the precursor polyp, with a skewed distribution toward a higher frequency of BRAFmutated serrated pathway CRC compared with the general population in which serrated polyps are not as common. We also demonstrated heterogeneity of CRC within a single patient who had synchronous CRCs showing different molecular profiles.
Another important finding of our study was the frequent occurrence of multiple CRCs identified in 26.3% of SP patients. One or multiple metachronous CRCs were present in 13.2% of patients who have had initial segmental resections, with a median interval of 10.5 years between CRC diagnoses. In general, patients with a diagnosis of CRC are at increased risk of developing metachronous CRCs when compared with the general population (standardized incidence ratio 1.3; 95% confidence interval, 1.1-1.5). 36 Fante et al 37 reported that 7% of all CRCs from a CRC registry were multiple. Metachronous CRCs were present in 1.5% of patients, with a higher prevalence in Lynch patients compared with non-Lynch patients (5.8% vs. 1.3%). Synchronous CRCs were reported in 2.5% of all patients. Multiple CRCs have been described from the outset in SP-associated CRC. 38, 39 Our data provide additional evidence that, as in other high-risk CRC syndromes, 40 when SP patients present with CRC, more extensive colonic resection should be considered for both the subsequent risk of metachronous cancer and future control of polyps. This is particularly important, because several studies have reported that a high proportion of interval CRCs, defined as CRCs diagnosed within 5 years of a complete colonoscopy, are serrated neoplasia pathway CRCs. 41, 42 This may be explained by the lower polyp detection rate reported for right-sided serrated polyps 43 or by the rapid progression of sessile serrated adenomas with dysplasia to adenocarcinoma, even for a polyp <10 mm in size. 44, 45 As nearly half of the CRCs in SP patients are serrated neoplasia pathway CRCs, they would be anticipated to have a significant risk of interval cancers. Boparai et al 8 reported 5 CRCs in SP patients diagnosed at followup intervals as short as 1 to 2 years. Moreover, not uncommonly the invasive component was found in serrated polyps <10 mm in size. In our series, 6 of the CRCs (13.3%) were <10 mm in size, thus supporting consideration of extensive colectomy when SP patients present with newly diagnosed CRCs. With multiple polyps and potentially unachievable colonoscopic removal of all polyps >5 mm, an alternative, as previously suggested, 46 is referral to a specialist tertiary center for endoscopic surveillance, with advanced imaging techniques, every 6 to 12 months. 12, 47, 48 As a retrospective study from multiple genetic clinics, our study has several limitations. Patients in our cohort likely represent the most severe phenotype of this heterogenous polyposis syndrome with high polyp burden, strong family history, and multiple CRCs. The availability of uneven tissue sections and varied quality of tumor DNA limited our ability to perform a wider range of molecular testing on all samples. Furthermore, until a genetic presymptomatic, predictive test is available, clinical studies of SP, with adequate numbers of cases, will continue to be limited by retrospective recruitment bias.
In summary, we report the largest series of CRCs diagnosed in the context of SP patients. These tumors are characterized by diversity in their molecular alteration profiles, encompassing features of at least the serrated neoplasia pathway and the traditional adenoma pathway. In addition, residual polyp histology showed lesions of both pathways in equal measure. These results suggest that serrated polyps are not the only precursor lesions of CRC in SP patients, and the role of atypical conventional adenomas requires consideration. After segmental colonic resection for CRC in SP patients, annual colonoscopic surveillance to remove all polyps >5 mm should be considered to reduce the risk of metachronous and interval CRCs. Advanced imaging techniques, although not routinely available, 49 may aid polyp detection. 50 If endoscopic control of polyps is not achievable and sessile serrated adenomas with cytologic dysplasia or conventional adenomas are present, subtotal colectomy should be considered. 12 
